Stockreport

Presentations at EADO Highlight Potential Impact of Castle Biosciences' DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer [Yahoo! Finance]

Castle Biosciences, Inc. - Common stock  (CSTL) 
Last castle biosciences, inc. - common stock earnings: 3/10 04:05 pm Check Earnings Report
PDF that patients foregoing an SLNB have low risk outcomes; Castle's poster on DecisionDx-Melanoma shows that patients foregoing an SLNB due to a DecisionDx-Melanoma test re [Read more]